A randomized multicenter, open label, controlled and non-comparative phase II study of anti-PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung cancer (SCLC)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Topotecan
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018.
- 24 Apr 2018 Status changed from recruiting to active, no longer recruiting.